Trial · NCT03918629
Results by group238
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 238
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Adjusted Geometric Mean Concentration (GMC) of Clostridium Difficile Toxin A and Toxin B Specific Neutralizing Antibodies at Month 7 for Evaluable Immunogenicity Population (EIP) | 2-Dose Clostridium Difficile Vaccine | Toxin A | 693.0 | 95% Confidence Interval 646.5 to 742.9 | Neutralization units per milliliter |
| Adjusted Geometric Mean Concentration (GMC) of Clostridium Difficile Toxin A and Toxin B Specific Neutralizing Antibodies at Month 7 for Evaluable Immunogenicity Population (EIP) | 3-Dose Clostridium Difficile Vaccine | Toxin A | 845.7 | 95% Confidence Interval 789.5 to 906.0 | Neutralization units per milliliter |
| Adjusted Geometric Mean Concentration (GMC) of Clostridium Difficile Toxin A and Toxin B Specific Neutralizing Antibodies at Month 7 for Evaluable Immunogenicity Population (EIP) | 2-Dose Clostridium Difficile Vaccine | Toxin B | 4166.2 | 95% Confidence Interval 3759.7 to 4616.7 | Neutralization units per milliliter |
| Adjusted Geometric Mean Concentration (GMC) of Clostridium Difficile Toxin A and Toxin B Specific Neutralizing Antibodies at Month 7 for Evaluable Immunogenicity Population (EIP) | 3-Dose Clostridium Difficile Vaccine | Toxin B | 7342.9 | 95% Confidence Interval 6633.1 to 8128.5 | Neutralization units per milliliter |
| Percentage of Participants Achieving Seroresponse for Clostridium Difficile Toxin A and Toxin B at Month 7 for EIP | 2-Dose Clostridium Difficile Vaccine | Toxin A | 32.2 | 95% Confidence Interval 28.9 to 35.5 | Percentage of participants |
| Percentage of Participants Achieving Seroresponse for Clostridium Difficile Toxin A and Toxin B at Month 7 for EIP | 3-Dose Clostridium Difficile Vaccine | Toxin A | 33.9 | 95% Confidence Interval 30.6 to 37.3 | Percentage of participants |
| Percentage of Participants Achieving Seroresponse for Clostridium Difficile Toxin A and Toxin B at Month 7 for EIP | 2-Dose Clostridium Difficile Vaccine | Toxin B | 56.7 | 95% Confidence Interval 53.1 to 60.2 | Percentage of participants |
| Percentage of Participants Achieving Seroresponse for Clostridium Difficile Toxin A and Toxin B at Month 7 for EIP | 3-Dose Clostridium Difficile Vaccine | Toxin B | 73.5 | 95% Confidence Interval 70.3 to 76.5 | Percentage of participants |
| Percentage of Participants With Local Reactions by Maximum Severity Through 7 Days After Dose 1 | 2-Dose Clostridium Difficile Vaccine | Pain at injection site: Mild | 19.1 | 95% Confidence Interval 16.7 to 21.7 | Percentage of participants |
| Percentage of Participants With Local Reactions by Maximum Severity Through 7 Days After Dose 1 | 3-Dose Clostridium Difficile Vaccine | Pain at injection site: Mild | 17.5 | 95% Confidence Interval 15.2 to 20.0 | Percentage of participants |
| Percentage of Participants With Local Reactions by Maximum Severity Through 7 Days After Dose 1 | 2-Dose Clostridium Difficile Vaccine | Pain at injection site: Moderate | 1.2 | 95% Confidence Interval 0.6 to 2.1 | Percentage of participants |
| Percentage of Participants With Local Reactions by Maximum Severity Through 7 Days After Dose 1 | 3-Dose Clostridium Difficile Vaccine | Pain at injection site: Moderate | 2.6 | 95% Confidence Interval 1.7 to 3.8 | Percentage of participants |
| Percentage of Participants With Local Reactions by Maximum Severity Through 7 Days After Dose 1 | 2-Dose Clostridium Difficile Vaccine | Pain at injection site: Severe | 0.0 | 95% Confidence Interval 0.0 to 0.4 | Percentage of participants |
| Percentage of Participants With Local Reactions by Maximum Severity Through 7 Days After Dose 1 | 3-Dose Clostridium Difficile Vaccine | Pain at injection site: Severe | 0.1 | 95% Confidence Interval 0.0 to 0.6 | Percentage of participants |
| Percentage of Participants With Local Reactions by Maximum Severity Through 7 Days After Dose 1 | 2-Dose Clostridium Difficile Vaccine | Pain at injection site: Potentially life threatening | 0.0 | 95% Confidence Interval 0.0 to 0.4 | Percentage of participants |
| Percentage of Participants With Local Reactions by Maximum Severity Through 7 Days After Dose 1 | 3-Dose Clostridium Difficile Vaccine | Pain at injection site: Potentially life threatening | 0.0 | 95% Confidence Interval 0.0 to 0.4 | Percentage of participants |
| Percentage of Participants With Local Reactions by Maximum Severity Through 7 Days After Dose 1 | 2-Dose Clostridium Difficile Vaccine | Redness: Mild | 0.9 | 95% Confidence Interval 0.4 to 1.7 | Percentage of participants |
| Percentage of Participants With Local Reactions by Maximum Severity Through 7 Days After Dose 1 | 3-Dose Clostridium Difficile Vaccine | Redness: Mild | 0.6 | 95% Confidence Interval 0.2 to 1.3 | Percentage of participants |
| Percentage of Participants With Local Reactions by Maximum Severity Through 7 Days After Dose 1 | 2-Dose Clostridium Difficile Vaccine | Redness: Moderate | 0.2 | 95% Confidence Interval 0.0 to 0.7 | Percentage of participants |
| Percentage of Participants With Local Reactions by Maximum Severity Through 7 Days After Dose 1 | 3-Dose Clostridium Difficile Vaccine | Redness: Moderate | 0.6 | 95% Confidence Interval 0.2 to 1.3 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03918629/results